#lillypharma

Lilly’s Oral GLP-1 Breakthrough Reshapes Obesity Drug Market as Novo Nordisk Faces New Rival

Lilly’s oral GLP-1 orforglipron shows strong Phase 3 results, shaking up the obesity drug market and challenging Novo Nordisk.